On January 27, 2022, the FDA announced its decision to not include Glycopyrrolate on the…
WINDSOR, CONN. (Feb. 18, 2021)– SCA Pharmaceuticals continues its aggressive expansion and implementation of growth strategies, and in doing so, has appointed Joe Akers as Chief Operating Officer. Akers will provide leadership and oversight of all operational functions and teams in order to expand manufacturing capacity to meet growing customer demand.
With more than 30 years of leadership experience in pharmaceutical company operations, Akers brings expertise in manufacturing, supply chain, global sourcing, network optimization, M & A and licensing, engineering, purchasing and integration. Paramount for SCA Pharma, Akers will leverage his cross-functional operations experience to support the company in unparalleled growth.
“Joe’s skillfulness in managing operations at pharma companies experiencing accelerated growth is exactly what SCA Pharma needs as we grow rapidly and are poised for greater expansion,” said Milton Boyer, CEO. “Even more importantly, Joe enjoys a reputation for having the utmost integrity, a value at the core of both SCA Pharma’s brand and market leadership position in sterile compounded products. I am delighted that Joe is coming aboard at SCA Pharma.”
Most recently, Akers worked with the Allergan integration at AbbVie, a $63-billion acquisition representing a global portfolio of products, facilities, and employees. Prior roles at Abbott and AbbVie include global sourcing; operations lead for separation of AbbVie from Abbott; and site head of Lake County operations, which included fermentation, Survanta, drug product manufacturing, and finished goods manufacturing.
“Meeting patients’ needs by providing hospitals with high-quality products with best-in-class customer care will only become more important as demand for SCA Pharma’s services continues to increase,” Akers said. “I am very excited to join the SCA Pharma team.”
Akers earned a bachelor’s of science degree in chemical engineering from Northwestern University and holds a master’s degree in business administration from Lake Forest Graduate School of Management.
SCA Pharma has commenced an ambitious construction plan to expand its two sterile pharmaceutical manufacturing sites in Windsor, Conn., and Little Rock, Ark. The expansion will increase SCA Pharma’s physical footprint by 50 percent and introduce significant new automation to enhance scalability. The company recently announced that it had entered into a definitive membership interest purchase agreement with The Vistria Group and Excellere Partners.